BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021
September 09, 2021 07:00 ET
|
BioXcel Therapeutics
Live webcast, Revolutionizing Drug Discovery and Development Through AI, to be held from 12:00 PM ET – 2:00 PM ET NEW HAVEN, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc....
BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
August 10, 2021 07:00 ET
|
BioXcel Therapeutics
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...
BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
July 28, 2021 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
July 19, 2021 07:30 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive...
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
June 23, 2021 08:29 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., June 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of...
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
June 22, 2021 16:01 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches...
BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021
June 18, 2021 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., June 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
May 26, 2021 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II
May 19, 2021 07:00 ET
|
BioXcel Therapeutics
FDA sets PDUFA action date for January 5, 2022 If approved, BXCL501 would represent the first major advancement in the acute treatment of agitation associated with schizophrenia and bipolar disorders...
BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference
May 11, 2021 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...